Answers are grounded in this paper and cite their sources.
Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders.
No takes yet. Share an insight, caveat, or question.
AdityaKumar Bubna (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: